Good Blood Sugar Control May Help Mild Diabetic Retinopathy Improve, New Study Finds

Diabetic retinopathy is eye damage that can develop when high blood sugar levels affect blood vessels in the retina over time. Mild non-proliferative diabetic retinopathy (mild NPDR) is an early stage where small bleeding and fluid leakage begin but vision isn't yet affected.

For years, doctors have wondered whether improvements in diabetes management—particularly with newer technologies like continuous glucose monitors (CGMs)—could help slow or even reverse early retinopathy. A new study published in Diabetes Technology & Therapeutics provides encouraging evidence by tracking adults with type 1 diabetes and mild NPDR for approximately five years.

The research team followed 113 adults (median age 39, median diabetes duration 21 years) who had mild NPDR detected through retinal screening between 2018 and 2020. After about five years, participants underwent repeat eye exams to see how their retinopathy had changed.

The results were encouraging: 57.5% of participants experienced regression—meaning their retinopathy resolved completely and no signs of the disease remained. Another 31% stayed stable, with mild NPDR persisting but not worsening. Only 11.5% progressed to more advanced stages (moderate or severe NPDR) or developed diabetic macular edema (fluid buildup affecting central vision).

The study examined both traditional and newer measures of glucose control. People whose retinopathy improved had lower HbA1c levels—a three-month average blood sugar marker—at their five-year follow-up compared to those without improvement.

Researchers also analyzed CGM-derived metrics, including time in range (the percentage of time glucose stayed within target) and glucose management indicator. These newer measures showed associations with retinopathy regression in initial analysis. However, when researchers accounted for HbA1c's strong influence, these CGM metrics did not independently predict improvement. In practical terms, this means HbA1c remains the most reliable single predictor, though the underlying glucose patterns that CGMs reveal are still important to overall control.

This study reflects real-world outcomes in contemporary diabetes care—settings where people have access to insulin, CGM technology, and intensive management support. The findings suggest that sustained improvements in blood sugar control can help early diabetic retinopathy stabilize or even reverse.

However, this research describes trends in a group; individual outcomes vary. If you have been diagnosed with diabetic retinopathy, a conversation with your eye doctor and diabetes care team about your specific situation, treatment goals, and management plan remains essential. Regular eye screening is also critical, as early detection and good glucose control offer the best opportunities for preserving vision.

Source: Diabetes technology & therapeutics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.